Mohammad Jahanzeb MD

PubMed

• 11 citations
  International experts consensus on optimal central vascular access device selection and management for patients with cancer.
  Mohammad Jahanzeb, Ching-Yang Wu, Howard Lim, Kei Muro, Lichao Xu
  The Journal of Vascular Access. 2025-09-01
• 2 citations
  A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive...
  Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, Carlos L Arteaga, Ximing J Yang
  Breast Cancer Research and Treatment. 2024-09-01
• 1 citations
  A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive...
  Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, Carlos L Arteaga, Ximing J Yang
  Research Square. 2024-04-29

Journal Articles

• “SWOG S0802: A Randomized Phase II Trial of Weekly Topotecan with and without Ziv-aflibercept in Patients with Platinum-Treated Small Cell Lung Cancer”  
  Allen J, Moon J, Redman M, Gadgeel S, Kelly K, Mack P, Saba H, Mohamed M, Jahanzeb M, and David R Gandara, Journal of Clinical Oncology/ J Clin Oncol., 1/7/2014
• “Adverse Event Management in Patients With Advanced Cancer Receiving Oral Everolimus: Focus on Breast Cancer”  
  Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A, Annals of Oncology, 1/1/2014
• “Malignant Pleural Mesothelioma”  
  Ettinger DS, Akerley, Jahanzeb M, et.al., JNatl Compr Canc Netw., 1/1/2012

Books/Book Chapters

• “Lung Cancer: A Practical Guide” 
  Page 111 - 123Raez L, Silva O, Jahanzeb MElsevier Limited2008
• NCCN Lung Cancer Treatment Guidelines for Patients, Version II 
  Jahanzeb M, et.al.JNCCN2004
• The Washington Manual of Oncology 
  Chapter: "Breast Cancer" 
  Page 112 - 142Chantler ML, and Jahanzeb MLippincott Williams & Wilkins2002

Abstracts/Posters

• A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer.
  J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR, Southwest Oncology Allen JW, Moon Group S0802, J Clin Oncol., 1/7/2014
• "The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic ...
  Tripathy D1, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S., 1/2/2014
• Pathway activation mapping metastatic breast cancer identifies potential organ-specific signatures: implications for patient stratification to targeted treatment.
  Pierobon M, Anthony SP, Reeder A, Nicholas Robert, D. Northfelt, M. Jahanzeb, Vocila L, Wulfkuhle J, Dunetz B, Liotta L, Petricoin E. F., San Antonio Breast Cancer Symposium, 1/1/2014

Lectures

• 9th Annual New Orleans Summer Cancer Meeting 
  New Orleans, LA - 1/1/2014
• “Lung Cancer” 
  Deland, FL - 1/1/2014
• “Targeted Therapy for Lung Cancer: A Case Based Presentation” 
  Jacksonville, FL - 1/1/2014

Other

• “Focus on Cytotoxic Therapy” 
  Jahanzeb M, Yardley D, Recent Progress in Metastatic Breast Cancer, Physicians’ Education Resource
  1/1/2013
• “Avastin Breast / Herceptin Breast” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2009
• “Current Debates in the Treatment of HER 2+ Metastatic Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2008